-
Simplify patient recruitment and targeting
- Patients’ recruitment through BioSerenity healthcare services in several therapeutic areas such as sleep diseases, neurology, and cardiology
- Creation and usage of patient cohorts for different therapeutic areas through our sleep centers
- Patients’ screening for inclusion into the most suitable clinical trials based on our medical devices, such as the Cardioskin and the Neuronaute
-
Phase 1 – SafetyAdverse events detection
-
Phase 2 – EfficacyAdverse events and side effect detection, dose related efficacy
-
Phase 3 – EffectivenessPatient screening and adverse events monitoring, large sample clinical efficacy
-
Phase 4 – Continuous studies for long-term effectiveness and safetyComparative effectiveness and real-world evidence
-
Enhance the sensitivity of the detection of physiological changes
- Monitor patients with wearable medical devices for a continuous monitoring of patients, even outside consultations and during follow-up period up to several months
- Detect physiological changes through measurement of multifactorial electrophysiologic signals during clinical trials and follow-up
- Improve detection and notification of potential side effect and other physiologic events through event markers incorporated in our devices and the associated applications ePRO (electronic Patient Reported Outcome)
-
Phase 1 – SafetyAdverse events detection
-
Phase 2 – EfficacyAdverse events and side effect detection, dose related efficacy
-
Phase 3 – EffectivenessPatient screening and adverse events monitoring, large sample clinical efficacy
-
Phase 4 – Continuous studies for long-term effectiveness and safetyComparative effectiveness and real-world evidence
-
Generate evidence of drug efficacy
- Limit standard deviations linked to cross-reviewers bias during analysis thanks to a centralized monitoring platform
- Limit standard deviations linked to cross-technologists bias during analysis thanks to worn medical devices allowing reproductible measurement
- Monitor patients with our medical devices during clinical trials in hospitals or remotely in ambulatory settings
- Monitor efficacy and continued safety of cardiac or neurological drugs
- Demonstrate drug efficacy and effectiveness by algorithms created by analyzing the collected data and allowing new biomarkers detection
-
Phase 1 – SafetyAdverse events detection
-
Phase 2 – EfficacyAdverse events and side effect detection, dose related efficacy
-
Phase 3 – EffectivenessPatient screening and adverse events monitoring, large sample clinical efficacy
-
Phase 4 – Continuous studies for long-term effectiveness and safetyComparative effectiveness and real-world evidence
-
Improve evidence generation and enrich real-world data
- Monitor patients with our medical devices operable in patients’ homes between consultations
- Track and display the data recorded based on our store and forward cloud-based systems, available for 15 years
- Develop real world data with our bench-to-bedside tools for continuous data flow
- Support translational medicine and better appreciate the patient’s journey through their disease monitoring
-
Phase 1 – SafetyAdverse events detection
-
Phase 2 – EfficacyAdverse events and side effect detection, dose related efficacy
-
Phase 3 – EffectivenessPatient screening and adverse events monitoring, large sample clinical efficacy
-
Phase 4 – Continuous studies for long-term effectiveness and safetyComparative effectiveness and real-world evidence
-
Build a platform for Artificial Intelligence
- Gather the recorded data during clinical trials in a unique cloud-based platform
- Create artificial intelligence algorithms with a double objective:
- during the trial improve the diagnostics and the monitoring;
- and after the trial, propose the best care pathway for patients
- Support scientific knowledge, facilitate identification of diseases and sequelae, and enhance physiopathology mechanisms comprehension
-
Phase 1 – SafetyAdverse events detection
-
Phase 2 – EfficacyAdverse events and side effect detection, dose related efficacy
-
Phase 3 – EffectivenessPatient screening and adverse events monitoring, large sample clinical efficacy
-
Phase 4 – Continuous studies for long-term effectiveness and safetyComparative effectiveness and real-world evidence

The Cardioskin can be used during clinical trials
This medical device is FDA cleared and CE marked.
It consists of a 15 leads ECG for up to 14 weeks of recording in health care facilities or in the patient’s home.
The Cardioskin can be used by investigators during clinical trials for:
- Patient screening and selection: identify the appropriate patient cardiac criteria for your clinical trial
- Patient monitoring during the trial to detect potential cardiac changes and cardiology drug efficacy and safety
- Patients long-term monitoring for drug effectiveness and safety
Available soon: the Neuronaute will be available for clinical trials use
It will allow remote EEG recording in health care facilities or in the patient’s home.
The Neuronaute can be used by investigators during clinical trials for:
- Patient screening and selection: identify the best patient neurologic criteria for your clinical trial
- Patient monitoring during the trial to detect potential neurological (EEG) changes and neurological (i.e.epilepsy) drug efficacy
- Patients long-term monitoring for drug effectiveness and safety
